Merrimack Pharmaceuticals
MACK
$15.12
Share price
0.33%
Change (1 day)
21.54%
Change (1 year)
Categories
P/S ratio for Merrimack Pharmaceuticals (MACK)
P/S ratio as of May 2024 (TTM): N/A
According to Merrimack Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2023 the company had a P/S ratio of N/A.
P/S ratio history for Merrimack Pharmaceuticals from 2012 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | N/A | |
| 2022 | N/A | |
| 2021 | N/A | |
| 2020 | N/A | |
| 2019 | N/A | |
| 2018 | N/A | |
| 2017 | N/A | -100% |
| 2016 | 8.64 | -15.8% |
| 2015 | 10.3 | -12.6% |
| 2014 | 11.7 | 2.59% |
| 2013 | 11.4 | -4.12% |
| 2012 | 11.9 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 2.49 | N/A | 🇫🇷 France |
 Geron GERN | > 1000 | N/A | 🇺🇸 USA |
 Clovis Oncology CLVS | 0.0885 | N/A | 🇺🇸 USA |
 AVEO Oncology
AVEO | 5.53 | N/A | 🇺🇸 USA |
 Eterna Therapeutics ERNA | 169 | N/A | 🇺🇸 USA |